Taro Yamanaka, Medical Oncologist at National Cancer Center Hospital, Japan, shared a post on X:
“Exciting news in gynecologic oncology!
Risovalisib (PI3Kα inhibitor) is now approved in Japan for PIK3CA-mt Ovarian Clear Cell Carcinoma.
While it’s a vital new precision medicine option, management of its unique side effects will be essential!”
Details on the Companion Diagnostics (CDx)
Other articles featuring Taro Yamanaka on OncoDaily.